首页> 外文期刊>Frontiers in bioscience: a journal and virtual library >Role of microRNAs in the development of hepatocellular carcinoma and drug resistance
【24h】

Role of microRNAs in the development of hepatocellular carcinoma and drug resistance

机译:MicroRNA在肝细胞癌发育中的作用和耐药性

获取原文
获取原文并翻译 | 示例
       

摘要

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide and has a relatively poor survival rate. Aside from liver transplantation, the most effective and leading curative measure for HCC is the chemotherapeutic agent sorafenib, which is a multikinase inhibitor used for treating late-stage HCC. However, the effects of sorafenib are short-lived because of rapid acquisition of multi-drug resistance (MDR) by tumor cells. MicroRNAs (miRNAs) have emerged as crucial regulatory molecules for almost every biochemical pathway in humans. The progression of HCC and acquired MDR are critically influenced by miRNAs through regulation of key genes in cell regulatory pathways. This review explores the involvement of miRNAs in the development of HCC and their role in key signaling pathways leading to MDR in HCC.
机译:肝细胞癌(HCC)是全世界癌症相关死亡的主要原因,生存率相对较差。 除了肝移植之外,HCC最有效和最有效的治疗措施是化学治疗剂索拉非尼,其是用于治疗后期HCC的多立酶抑制剂。 然而,由于肿瘤细胞快速获取多药物抗性(MDR),因此Sorafenib的效果是短暂的。 MicroRNA(miRNA)已经成为几乎每种生化途径的关键调节分子。 HCC和获得的MDR的进展通过调节细胞调节途径的关键基因来严重影响MIRNA。 本综述探讨了MiRNA参与HCC的开发及其在通往HCC中MDR的关键信号通路中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号